- 697 views
- 92 pdf downloads
Vol. 5, Issue 2, 2018November 29, 2017 EDT
Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
1.
Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, et al. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. JHEOR. 2017;5(2):162-174. doi:10.36469/9808